ENHERTU Distribution

Specialty Distributors
ENHERTU will primarily be distributed through Specialty Distributors via the buy-and-bill process.

<table>
<thead>
<tr>
<th>Specialty Distributor</th>
<th>Phone number</th>
<th>Fax number</th>
<th>Website</th>
</tr>
</thead>
<tbody>
<tr>
<td>ASD Healthcare</td>
<td>1-800-746-6273</td>
<td>1-800-547-9413</td>
<td><a href="http://www.asdhealthcare.com">www.asdhealthcare.com</a></td>
</tr>
<tr>
<td>Cardinal Health Specialty Distribution</td>
<td>1-855-855-0708</td>
<td>1-614-553-6301</td>
<td>specialtyonline.cardinalhealth.com</td>
</tr>
<tr>
<td>McKesson Plasma and Biologics</td>
<td>1-877-625-2566</td>
<td>1-888-752-7626</td>
<td><a href="http://www.mckesson.com/pharmaceutical-distribution/plasma-biologics">www.mckesson.com/pharmaceutical-distribution/plasma-biologics</a></td>
</tr>
<tr>
<td>McKesson Specialty Health</td>
<td>1-800-482-6700</td>
<td>1-800-289-9285</td>
<td>mckesson specialtyhealth.com</td>
</tr>
<tr>
<td>Oncology Supply</td>
<td>1-800-633-7555</td>
<td>1-800-248-8205</td>
<td>oncologysupply.com</td>
</tr>
</tbody>
</table>

The ENHERTU distribution program includes extended payment terms to AstraZeneca/Daiichi Sankyo authorized distributors. Health care providers should contact their distributor to understand specific payment terms available to them from their distributor.

Specialty Pharmacy Providers
ENHERTU is dispensed through a limited network of specialty pharmacies.

<table>
<thead>
<tr>
<th>SPP</th>
<th>Phone number</th>
<th>Fax number</th>
<th>Website</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accredo</td>
<td>1-877-783-2262</td>
<td>1-888-302-1028</td>
<td><a href="http://www.accredo.com">www.accredo.com</a></td>
</tr>
<tr>
<td>Biologics</td>
<td>1-800-850-4306</td>
<td>1-800-823-4506</td>
<td>biologics.mckesson.com</td>
</tr>
<tr>
<td>CVS Specialty Pharmacy</td>
<td>1-800-237-2767</td>
<td>1-800-323-2445</td>
<td>cvsspecialty.com</td>
</tr>
<tr>
<td>Onco360</td>
<td>1-877-662-6633</td>
<td>1-877-662-6355</td>
<td>onco360.com</td>
</tr>
</tbody>
</table>

Please see Important Safety Information on page 2, and click here for full Prescribing Information, including Boxed WARNING, and click here for Medication Guide.
ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of breast cancer who have received two or more prior anti-HER2-based regimens. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

**WARNING:** INTERSTITIAL LUNG DISEASE and EMBRYO-FETAL TOXICITY

- Interstitial lung disease (ILD) and pneumonitis, including fatal cases, have been reported with ENHERTU. Monitor for and promptly investigate signs and symptoms including cough, dyspnea, fever, and other new or worsening respiratory symptoms. Permanently discontinue ENHERTU in all patients with Grade 2 or higher ILD/ pneumonitis. Advise patients of the risk and to immediately report symptoms.
- Exposure to ENHERTU during pregnancy can cause embryo-fetal harm. Advise patients of these risks and the need for effective contraception.

**Contraindications**
None.

**WARNINGS AND PRECAUTIONS**

**Interstitial Lung Disease / Pneumonitis**
Severe, life-threatening, or fatal interstitial lung disease (ILD), including pneumonitis, can occur in patients with unresectable or metastatic HER2-positive breast cancer who have received ENHERTU. In clinical studies, of the 234 patients with unresectable or metastatic HER2-positive breast cancer treated with ENHERTU, ILD occurred in 9% of patients. Fatal outcomes due to ILD and/or pneumonitis occurred in 2.6% of patients treated with ENHERTU. Median time to first onset was 4.1 months (range: 1.2 to 8.3).

Advises patients to immediately report cough, dyspnea, fever, and/or any new or worsening respiratory symptoms. Monitor patients for signs and symptoms of ILD. Promptly investigate evidence of ILD. Evaluate patients with suspected ILD by radiographic imaging. Consider consultation with a pulmonologist. For asymptomatic ILD/pneumonitis (Grade 1), interrupt ENHERTU until resolved to Grade 0, then if resolved in ≥28 days from date of onset, maintain dose. If resolved in ≥28 days from date of onset, reduce dose one level. Consider corticosteroid treatment as soon as ILD/pneumonitis is suspected (e.g., ≥1 mg/kg prednisolone or equivalent). If asymptomatic ILD/pneumonitis (Grade 2 or greater), permanently discontinue ENHERTU. Promptly initiate corticosteroid treatment as soon as ILD/pneumonitis is suspected (e.g., ≥1 mg/kg prednisolone or equivalent). Upon improvement, follow by gradual taper (e.g., 4 weeks).

**Neutropenia**
Severe neutropenia, including febrile neutropenia, can occur in patients treated with ENHERTU. Of the 234 patients with unresectable or metastatic HER2-positive breast cancer who received ENHERTU, a decrease in neutrophil count was reported in 30% of patients and 16% had Grade 3 or 4 events. Median time to first onset was 1.4 months (range: 0.3 to 18.2). Febrile neutropenia was reported in 1.7% of patients.

Monitor complete blood counts prior to initiation of ENHERTU and prior to each dose, and as clinically indicated. Based on the severity of neutropenia, ENHERTU may require dose interruption or reduction. For Grade 3 neutropenia (Absolute Neutrophil Count [ANC] <1.0 to 0.5 x 10^9/L) interrupt ENHERTU until resolved to Grade 2 or less, then maintain dose. For Grade 4 neutropenia (ANC <0.5 x 10^9/L) interrupt ENHERTU until resolved to Grade 2 or less. Reduce dose by one level. For febrile neutropenia (ANC <1.0 x 10^9/L and temperature >38.3°C or a sustained temperature of ≥38°C for more than 1 hour), interrupt ENHERTU until resolved. Reduce dose by one level.

**Left Ventricular Dysfunction**
Patients treated with ENHERTU may be at increased risk of developing left ventricular dysfunction. Left ventricular ejection fraction (LVEF) decrease has been observed with anti-HER2 therapies, including ENHERTU. In the 234 patients with unresectable or metastatic HER2-positive breast cancer who received ENHERTU, two cases (0.9%) of asymptomatic LVEF decrease were reported. Treatment with ENHERTU has not been studied in patients with a history of clinically significant cardiac disease or LVEF <50% prior to initiation of treatment.

Assess LVEF prior to initiation of ENHERTU and at regular intervals during treatment as clinically indicated. Manage LVEF decrease through treatment interruption. Permanently discontinue ENHERTU if LVEF of <40% or absolute decrease from baseline of >20% is confirmed. When LVEF is ≥45% and absolute decrease from baseline is 10-20%, continue treatment with ENHERTU. When LVEF is 40-45% and absolute decrease from baseline is <10%, continue treatment with ENHERTU and repeat LVEF assessment within 3 weeks. When LVEF is 40-45% and absolute decrease from baseline is >20%, interrupt ENHERTU and repeat LVEF assessment within 3 weeks. If LVEF has not recovered to within 10% from baseline, permanently discontinue ENHERTU. If LVEF recovers to within 10% from baseline, resume treatment with ENHERTU at the same dose. When LVEF is <40% or absolute decrease from baseline of >20% is confirmed, permanently discontinue ENHERTU. Advise patients of the risk and to immediately report symptoms.

**Embryo-Fetal Toxicity**
ENHERTU can cause fetal harm when administered to a pregnant woman. Advise patients of the potential risks to a fetus. Verify the pregnancy status of females of reproductive potential prior to initiation of ENHERTU. Advise females of reproductive potential to use effective contraception during treatment and for at least 7 months following the last dose of ENHERTU. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ENHERTU and for at least 4 months after the last dose of ENHERTU.

**Adverse Reactions**
The safety of ENHERTU was evaluated in a pooled analysis of 234 patients with unresectable or metastatic HER2-positive breast cancer who received at least one dose of ENHERTU 5.4 mg/kg in DESTINY-Breast01 and Study DS8201-A-J101. ENHERTU was administered by intravenous infusion once every three weeks. The median duration of treatment was 7 months (range: 0.7 to 31).

Serious adverse reactions occurred in 20% of patients receiving ENHERTU. Serious adverse reactions ≥1% of patients who received ENHERTU were interstitial lung disease, pneumonia, vomiting, nausea, cellulitis, hypokalemia, and intestinal obstruction. Fatalities due to adverse reactions occurred in 4.3% of patients including interstitial lung disease (2.6%), and the following events occurred in one patient each (0.4%): acute hepatic failure/acute kidney injury, general physical health deterioration, pneumonia, and hemmorhagic shock.

ENHERTU was permanently discontinued in 9% of patients, of which ILD accounted for 6%. Dose interruptions due to adverse reactions occurred in 33% of patients treated with ENHERTU. The most frequent adverse reactions (≥3%) associated with dose reduction for ILD were neutropenia, anemia, thrombocytopenia, upper respiratory tract infection, fatigue, nausea, and ILD. Dose reductions occurred in 18% of patients treated with ENHERTU. The most frequent adverse reactions (≥2%) associated with dose reduction were fatigue, nausea, and neutropenia.

The most common adverse reactions (frequency ≥20%) were nausea (79%), fatigue (59%), vomiting (47%), alopecia (46%), constipation (35%), decreased appetite (32%), anemia (31%), neutropenia (29%), diarrhea (29%), leukopenia (22%), cough (20%), and thrombocytopenia (20%).

**Use in Specific Populations**

- **Pregnancy:** ENHERTU can cause fetal harm when administered to a pregnant woman. Advise patients of the potential risks to a fetus. There are clinical considerations if ENHERTU is used in pregnant women, or if a patient becomes pregnant within 7 months following the last dose of ENHERTU.
- **Lactation:** There are no data regarding the presence of ENHERTU in human milk, the effects on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions in nursing infants from ENHERTU and/or the potential for serious adverse reactions from all anti-HER2 therapies, advise females of reproductive potential prior to initiation of ENHERTU. Advise breastfeeding mothers not to breastfeed during treatment with ENHERTU and for 7 months after the last dose.
- **Females and Males of Reproductive Potential:** Pregnancy testing: Verify pregnancy status of females of reproductive potential prior to initiation of ENHERTU. Contraception: Females: ENHERTU can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with ENHERTU and for at least 7 months following the last dose. Males: Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ENHERTU and for at least 4 months following the last dose. Infertility: ENHERTU may impair male reproductive function and fertility.
- **Pediatric Use:** Safety and effectiveness of ENHERTU have not been established in pediatric patients.
- **Geriatric Use:** Of the 234 patients with HER2-positive breast cancer treated with ENHERTU 5.4 mg/kg, 26% were ≥65 years and 5% were ≥75 years. No overall differences in efficacy were observed between patients ≥65 years of age compared to younger patients. There was a higher incidence of Grade 3–4 adverse reactions observed in patients aged ≥75 years (53%) as compared to younger patients (42%).
- **Hepatic Impairment:** In patients with moderate hepatic impairment, due to potentially increased exposure, closely monitor for increased toxicities related to the topoisomerase inhibitor.

To report SUSPECTED ADVERSE REACTIONS, contact Daiichi Sanky, Inc. at 1-877-437-7763 or FDA at 1-800-FDA-1088 or fda.gov/medwatch. Please click here for full Prescribing Information, including Boxed WARNING, and click here for Medication Guide.